Premium
Serum biomarkers TARC and IL ‐6 predict relapse risk in H odgkin lymphoma patients undergoing autologous hematopoietic cell transplantation
Author(s) -
Bachanova V.,
Trottier B.J.,
Cao Q.,
Weisdorf D.J.,
Burns L.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2439_66
Subject(s) - medicine , hazard ratio , cumulative incidence , lymphoma , clinical endpoint , oncology , biomarker , transplantation , gastroenterology , proportional hazards model , immunology , confidence interval , clinical trial , biology , biochemistry